Atom Bioscience and Pharmaceutical has submitted a Hong Kong Stock Exchange (HKEX) listing application with CITIC Securities as sole sponsor following its Series D funding round valuing the company at RMB 3.05 billion (USD 430 million). The China-based biotech focuses on metabolic disorders with lead candidate ABP-671, a URAT1 inhibitor for gout and hyperuricaemia currently in Phase IIb/III trials in both China and the US. The novel chemical structure eliminates hepatotoxicity risks associated with benzbromarone while demonstrating superior uric acid reduction efficacy and target selectivity.

Founded in 2012, Atom reported losses of RMB 97.4 million in 2023 and RMB 434.1 million in 2024 with no commercial products launched yet. The company's pipeline addresses full-spectrum gout management from hyperuricaemia to chronic gout, acute flares and tophi resolution.

PharmCube's MedAlpha® shows that Atom last year received USD 168 million from a strategic investment. Click here to request a free trial for MedAlpha®.